Trial Profile
A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Amgen
- 11 Oct 2019 Status changed to discontinued.
- 04 Oct 2019 Status changed from active, no longer recruiting to completed.
- 13 Sep 2019 Planned End Date changed from 23 Dec 2023 to 30 Sep 2019.